Novartis: Lymphoma, Large B-Cell, Diffuse trials

The registry lists 31 Lymphoma, Large B-Cell, Diffuse studies with Novartis as lead sponsor. 4 are open to participants now and 8 have results posted.

Phase 1 10Phase 2 8Phase 3 3No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-term Follow up Local Registry Study of Kymriah in South KoreaRecruitingNCT06785818
• Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruitingNCT05541341
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/2
• Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 3
• Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCLCompletedNCT04134936Phase 1Results posted
• Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedNCT03610724Phase 2Results posted
• Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin LymphomaCompletedNCT03570892Phase 3Results posted
• PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic MalignanciesCompletedNCT03365791Phase 2Results posted
• Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsCompletedNCT02445248Phase 2Results posted
• Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCLCompletedNCT02399085Phase 2Results posted
• Safety and Efficacy of BKM120 in Relapsed and Refractory NHLCompletedNCT01693614Phase 2Results posted
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyCompletedNCT00790036Phase 3Results posted
• A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT07103486
• Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS DataCompletedNCT06392763
• Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.CompletedNCT06271369
• Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient SettingsCompletedNCT05918809
• Comparison of Clinical Outcomes Among Patients Treated With TisagenlecleucelCompletedNCT05541328
• Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT05366257
• CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)CompletedNCT05349201
• Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
• Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCLCompletedNCT04697160
• Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnNCT04456023Phase 2
• Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCLApproved for marketingNCT04300803
• Lenalidomide Monotherapy in R/R DLBCLCompletedNCT04150328
• Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruitingNCT03960840Phase 1/2
• Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
• Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
• Safety and Efficacy of MAK683 in Adult Patients With Advanced MalignanciesTerminatedNCT02900651Phase 1
• Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedNCT01854606Phase 1
• Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaTerminatedNCT01402440Phase 1
• Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1